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We reported that the clinical efficacy of
dendritic cell–based vaccination is strongly
associated with immunologic responses
in relapsed B-cell non-Hodgkin lymphoma
(B-NHL) patients. We have now investi-
gated whether postvaccination antibod-
ies from responders recognize novel
shared NHL-restricted antigens. Immuno-
histochemistry and flow cytometry showed
that they cross-react with allogeneic B-
NHLs at significantly higher levels than
their matched prevaccination samples or
nonresponders’ antibodies. Western blot
analysis of DOHH-2 lymphoma proteome
revealed a sharp band migrating at ap-
proximately 100 to 110 kDa only with post-
vaccine repertoires from responders.
Mass spectrometry identified heat shock
protein-105 (HSP105) in that molecular
weight interval. Flow cytometry and immu-
nohistochemistry disclosed HSP105 on
the cell membrane and in the cytoplasm
of B-NHL cell lines and 97 diagnostic
specimens. A direct correlation between
HSP105 expression and lymphoma ag-
gressiveness was also apparent. Treat-
ment of aggressive human B-NHL cell
lines with an anti-HSP105 antibody had
no direct effects on cell cycle or apopto-
sis but significantly reduced the tumor
burden in xenotransplanted immunodefi-
cient mice. In vivo antilymphoma activity
of HSP105 engagement was associated
with a significant local increase of Gran-
zyme B killer cells that very likely contrib-
uted to the tumor-restricted necrosis. Our
study adds HSP105 to the list of nononco-
genes that can be exploited as antilym-
phoma targets. (Blood. 2011;118(16):
4421-4430)
Introduction
B-cell non-Hodgkin lymphomas (B-NHLs) are lymphoprolifera-
tive malignancies that encompass different biologic and histologic
subtypes and arise from mature B cells within secondary lymphoid
organs.1,2 Although these tumors are highly sensitive to both
chemotherapy and radiotherapy,3 the ultimate goal of curing all
NHLs remains to be attained. The last 20 years have demonstrated
that the chimeric monoclonal antibody (mAb) rituximab has been
the most valuable addition to the B-NHL treatment armamen-
tarium. At present, its combination with poly-chemotherapy still
represents the standard of choice for the treatment of both indolent
and aggressive B-NHL.4,5 However, given the difficulties in the
management of relapse and resistance to rituximab6,7 and the late
toxicities associated with its administration,8 it seems that treat-
ment of B-NHL may have reached a new plateau. Alternative
approaches as well as new molecular targets are thus required to
ameliorate management and clinical outcome of the many patients
that become resistant to rituximab.
We have recently reported that vaccination with autologous
dendritic cells (DCs) pulsed with autologous killed tumor cells
elicited clinical responses associated with tumor-specific immune
activation in 6 of 18 relapsed indolent B-NHL patients.9 This points
to the existence of novel, NHL-restricted therapeutic antigens.
Immunohistochemistry (IHC) using patients’ circulating immuno-
globulins (Igs) on autologous lymphoma biopsies showed that our
protocol induced tumor-restricted Ab responses only when it was
clinically efficacious.9
In the present study, we have looked to see whether the
antitumor humoral immunity developed in responders was directed
against shared NHL-restricted antigen(s). Demonstration of such
cross-reactivity constituted the prerequisite for exploitation of the
responders’ Ab repertoires to discover new lymphoma antigens to
be targeted in NHL immunotherapy. We have used an appropriately
modified serological proteome-based approach (SERPA) to iden-
tify the proteins differentially recognized by these repertoires.
HSP105 was one of these proteins. It has been extensively shown
that HSP105/110, together with HSP90, HSP70, HSP60, HSP40,
and HSP27 classes of proteins, guide the normal folding, intracellu-
lar disposition, and proteolytic turnover of many of the key
regulators of cell growth, differentiation, and survival, including
HER2, mutant HER1, c-KIT, BCR-ABL, Akt, Cdk4, BRAF,
HIF1-, p53, and other oncoproteins.10-12 Despite the focus on
oncogenes as cancer therapy targets, sound experimental evidence
demonstrates that targeting stress proteins could also be effective
by promoting the destabilization of their client proteins.10,13-16
Our findings show that HSP105 is immunogenic in NHL
oncotype and expressed on the plasma membrane and in the
Submitted June 29, 2011; accepted August 11, 2011. Prepublished online as
Blood First Edition paper, August 22, 2011; DOI 10.1182/blood-2011-06-364570.
*S.M.P. and M.D.N. contributed equally to this study.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 USC section 1734.
© 2011 by The American Society of Hematology
4421BLOOD, 20 OCTOBER 2011  VOLUME 118, NUMBER 16
For personal use only.on November 10, 2016. by guest  www.bloodjournal.orgFrom 
cytoplasm of human B-NHL cell lines and specimens, with
significantly higher intensity in highly proliferating aggressive
lymphoma. In addition, its direct targeting by a specific Ab
significantly impairs lymphoma growth and causes extensive
necrosis of tumor and associated stroma cells, probably through the
recruitment of Granzyme B–producing natural killer (NK) cells at
the tumor site. Taken as a whole, our results point to HSP105 as a
novel, attractive candidate biotarget for B-NHL therapy.
Methods
Cohort samples
The pre- and the postvaccination Ab repertoires from 7 of 18 patients with a
history of relapsed indolent B-NHL enrolled in our previous pilot trial of
DC-based vaccination (nos. 1, 2, 5, 8, 13, 14, and 17)9 were analyzed. Four
were responders (2 complete and 2 partial remissions) according to the
NHL International Workshop Criteria.17 Patients’ serum was collected from
peripheral blood (PB), harvested before and 6 months after the last injection
of the vaccine. Malignant B cells had been isolated from diagnostic tumor
biopsies using a high-gradient immunomagnetic technique, according to the
manufacturer’s instructions (CD19 microbeads; Miltenyi Biotec), and had
been cryopreserved until used. Written informed consent for the investiga-
tional use of lymphocytes, serum samples, and tumor tissue had been
obtained in accordance with the Helsinki Declarations revised and amended
in 2008.
Cell lines and culture conditions
The following human neoplastic cell lines were used: DOHH-2 and SC-1
(follicular lymphoma [FL]); RL-19, SU-DHL-6, KARPAS-422, and SU-
DHL-4 (transformed diffuse large B-cell lymphoma [DLBCL]); GRANTA-
519 (mantle cell lymphoma); RAJI and NAMALWA (Burkitt lymphoma
[BL]); HDMYZ and L-540 (Hodgkin lymphoma); KMS-11 (multiple
myeloma), MOLT-4 (acute T lymphocytic leukemia), and SU-DHL-1
(anaplastic large T cell lymphoma). Cell lines were purchased from
DSMZ and were routinely maintained in RPMI 1640 medium (Lonza
Switzerland) supplemented with 10% (volume/volume) FBS (Lonza Swit-
zerland) and L-glutamine (Lonza Switzerland) in a humidified chamber
with 5% CO2 at 37°C.
Immunohistochemistry
To evaluate NHL-specific cross-reactivity of patients’ Ab repertoires, total
Igs were purified from serum samples of 7 vaccinated patients and 8 healthy
donors, conjugated with biotin and used for IHC as described.9
IHC evaluation of HSP105 and Ki-67 expression was performed on
tissue sections of indolent (54 cases), aggressive B-NHL (43 cases), or
nonmalignant lymph nodes (26 cases) obtained from the Tissue Bank of
Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS)
Istituto Nazionale dei Tumori di Milano. For these stainings, epitope
retrieval was performed on formalin-fixed and paraffin-embedded tissue
sections treated with 6mM citrate buffer for 6 minutes at 96°C or 2mM
EDTA (pH 8) for 15 minutes at 98°C, respectively. Endogenous peroxidase
activity was blocked by incubation with 30% hydrogen peroxide in PBS for
40 minutes, followed by treatment with normal goat serum (1:50; Dako
Denmark) for 40 minutes at room temperature. Mouse anti–human Ki-67
mAb (1:100; Dako Denmark) and rabbit polyclonal anti–human HSP105
Ab (1:1500, clone N-187; Santa Cruz Biotechnology) were, respectively,
incubated for 1 hour at room temperature or overnight at 4°C. Biotin-
conjugated anti–mouse or antirabbit IgG (1:100 and 1:200, respectively;
Dako Denmark) was added for 1 hour at room temperature, and the
immunoreactivity was revealed by HRP-conjugated streptavidin (1:300;
Dako Denmark) and visualized using 3,3-diaminobenzidine (Sigma-
Aldrich). Tissue sections were lastly counterstained with hematoxylin.
Anti–Ki-67 Ab immunoreactivity was scored as weak (5%-10%), moderate
(10%-30%), and strong ( 30%) according to the number of positive
nuclei in tumor cells. A combining score (CS) was arbitrarily defined by
the pathologists to quantify HSP105 expression (0-2 indicates low; 3-5,
moderate; and 6 or 7, high) based on the percentage of HSP105 neoplastic
cells (0 indicates  1%; 1,  1% and  20%; 2,  20% and  50%;
3,  50% and  80%; and 4,  80%) and HSP105 staining intensity (1-3;
1 indicates weak; 2, moderate; and 3, strong).
Flow cytometry
Flow cytometry was performed on live primary malignant B cells isolated
from tumor biopsies, live or fixed malignant B- and T-cell lines, and pooled
donor PB mononuclear cells (PBMCs). Cells were incubated with FcR
blocking reagent (Miltenyi Biotec) in the presence of biotin-conjugated
human Igs (100 g/mL) or rabbit polyclonal anti–human HSP105 Ab
(4 g/mL; Santa Cruz Biotechnology) for 40 minutes on ice. FITC-labeled
streptavidin (1:80; BD Biosciences PharMingen) and goat anti–rabbit IgG
(KPL) were used to reveal the specific reactivity of primary Abs.
Cytoplasmic stainings were carried out after fixation and permeabilization
using BD Cytofix/Cytoperm (BD Biosciences PharMingen), according to
the manufacturer’s instructions. PBMCs were concurrently stained with
peridinin chlorophyll protein-labeled CD3 and allophycocyanin-labeled
CD19 (BD Biosciences) to detect HSP105 expression in CD3- or CD19-
gated subsets in multiparametric flow cytometry evaluations. To obtain
absolute cell counts, cell samples were supplemented with a fixed amount
of Flow-Count beads (Beckman Coulter) and stained with propidium iodide
(PI). Cell counts per microliter were calculated from the following
equation: counted viable cells  total beads/counted beads. Flow cytom-
etry of apoptosis was performed as described.18 For cell-cycle analysis,
cells were fixed in 70% ethanol and DNA was stained by overnight
incubation with 2.5 g/mL PI (Calbiochem) in the presence of 25 g/mL
RNAse (Sigma-Aldrich) at 4°C. Data were acquired using BD CellQuest
Version 3.3 software (BD Biosciences) and processed with the FlowJo
Version 8.7.1 software (TreeStar) version for Macintosh Pro personal
computer.
OFFGEL fractionation
DOHH-2 whole lysate (1 mg) was isoelectrofocused using a 3100 OFFGEL
Fractionator (Agilent Technologies) with an immobilized pH 3 to 10 gradi-
ent strip (GE Healthcare) and a 24-well manifold, according to the
manufacturer’s instructions.19 Focusing was stopped after total voltage
reached 64 kV/h, and protein fractions were purified with 2-dimensional
clean-up kit (GE Healthcare) and dissolved in Laemmli buffer. Nine-tenths
of the volume was resolved by 1-dimensional SDS-PAGE, followed by
silver staining, and one-tenth was transferred to a nitrocellulose membrane
according to standard procedures.
Western blot and immunoprecipitation
Normal CD3 T and CD19 B cells, immunomagnetically selected from
donor PB (Pan T-cell isolation kit and CD19 microbeads; Miltenyi Biotec),
and tumor cell lines were solubilized for 40 minutes at 0°C with Laemmli
buffer, as described.18
For immunoprecipitation, DOHH-2 lysates were precleared for 30 min-
utes at 4°C with immunopure immobilized protein A/G Sepharose (Pierce
Chemical) previously equilibrated in lysis buffer. Protein extracts (3 mg/
sample) were incubated for 2 hours at 4°C with 3 g rabbit polyclonal
anti-HSP105 Ab (Santa Cruz Biotechnology) or rabbit normal serum as
negative control, and then with protein A/G-Sepharose (60 L/sample,
previously equilibrated in lysis buffer) overnight at 4°C on a rocker.
Sepharose-bound immunocomplexes were washed 3 times with lysis buffer
and eluted in loading buffer.
Eluted immunoprecipitated proteins, OFFGEL protein fractions or lym-
phoma cell lysates, mixed with loading buffer and denatured on heating for
5 minutes at 95°C, were subjected to electrophoresis on 4%-12% or 3%-8%
NuPAGE Bis-Tris precast polyacrylamide gels (Invitrogen). Separated
proteins were transferred onto nitrocellulose membrane (Hybond-C Super;
GE Healthcare) in 20% ethanol NuPAGE transfer buffer (Invitrogen),
stained with Ponceau red solution, washed extensively with 0.5% Triton
X-100 PBS, and saturated overnight at 4°C in blocking solution (5%
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low-fat milk, 0.1% Triton X-100 PBS) before incubation with biotin-
conjugated patients’ Igs (100 g/mL), rabbit polyclonal antihuman HSP105
Ab (1g/mL, Santa Cruz Biotechnology), mouse monoclonal antihuman
HSP105 mAb (1:1000, Abcam), or rabbit polyclonal anti–human actin Ab
(1:1000, Sigma-Aldrich) in blocking solution for 1 hour at room tempera-
ture. Immunoreactive proteins were visualized with appropriate secondary
Abs: HRP-conjugated donkey anti–rabbit Igs (1:10 000; GE Healthcare) or
HRP-conjugated streptavidin (1:10 000; GE Healthcare), and signals were
detected using an enhanced ECL system (ECL Western Blotting Detection
Reagents; GE Healthcare), according to the manufacturer’s protocol.
In-gel tryptic digestion, MALDI-TOF-MS
To identify the proteins differentially recognized by postvaccination Igs of
responders within the 1-dimensionally separated DOHH-2 fractions, pro-
tein bands were excised from silver-stained preparative gel and analyzed by
matrix-assisted laser desorption/ionization time-of-flight mass spectrom-
etry (MALDI-TOF-MS), as described.20 Briefly, proteins were in-gel
digested with trypsin (13 ng/L) for 18 hours at 37°C. The peptide mixture
obtained from each band was analyzed with MALDI-TOF Voyager-DE
STR (Applied Biosystems), equipped with a nitrogen laser (337 nm).
Spectra were analyzed with Aldente software (http://web.expasy.org/cgi-bin/
aldente/help.pl?intro.html). Input was searched according to the UniProtKB/
SwissProt database (predefined taxon: mammalia; spectrometer internal
error max: 25). Only proteins identified in at least 3 independent experi-
ments were considered.
In vivo experiments
Severe combined immunodeficiency (SCID) mice (6-8 weeks old) with
body weight of 20-25 g were purchased from Charles River.
Mice were injected subcutaneously with 10 106 NAMALWA (54 mice)
and SU-DHL-4 (36 mice) cells. When tumors reached 0.05 to 0.07 cm3,
mice were randomized in 3 groups (6 mice/group, for a total of 3 and
2 experiments with NAMALWA and SU-DHL-4 models, respectively) to
receive 3 intraperitoneal injections of 1 mg/mL rabbit polyclonal anti–
human HSP105 or matched rabbit IgG isotype (250 g/mouse, glycerol-
and azide-free preparation for in vivo use, Santa Cruz Biotechnology) or
NaCl solution 0.9% (250 L/mouse). Tumors were calibrated twice a week,
and tumor volume was calculated as 0.5  d12  d2, where d1 and d2 are
the shortest and the longest diameters, respectively.
In vivo tumor growth was also evaluated in 3 mice/group by nuclear
magnetic resonance (NMR) 24 hours after the second treatment. NMR
imaging was performed with 1.5-T systems (Achieva, Philips) using similar
pulse sequences. In all cases, coronal short -inversion recovery sequences,
axial turbo-spin-echo T2-weighted sequences and axial and coronal unen-
hanced turbo-spin-echo T1-weighted sequences were followed by axial and
coronal contrast-enhanced turbo-spin-echo T1-weighted sequences (section
thickness 2 mm).
After 24 hours from the last treatment, tumors were excised and
processed for IHC. Paraffin-embedded biopsies from NAMALWA and
SU-DHL-4 xenografts were evaluated for HSP105 and Ki-67 expression as
described in the previous paragraph. CD45, CD56, and Granzyme B
immunostainings were performed on tissue sections from tumor xenografts
using the following primary Abs: mouse anti–human CD45 (clones RP2/18
and RP2/22, Novocastra), rat anti–mouse CD56 (clone H28.123, Abcam),
and rat anti–mouse Granzyme B (clone 16g6, eBioscience). Binding of
primary Abs was revealed using the streptavidin-biotin-peroxidase complex
method and 3-3-diaminobenzidine as chromogenic substrate.
Experimental protocols were approved by the Ethical Committee for
Animal Experimentation of the Fondazione IRCCS Istituto Nazionale dei
Tumori di Milano, according to the Italian legislation (Legislative Order
No. 116 of 1992, as amended), which implements the EU 86/109 Directive.
Statistical analyses
The 2-sided Student t test (P  .05) for unpaired data was used to detect
statistically significant differences. The nonparametric Spearman rank
correlation was used to measure the degree of association between
2 variables. Tumor volume data from the in vivo study were analyzed by
2-way ANOVA, and individual group comparisons were evaluated with the
Bonferroni posttest. Statistical analyses were performed on Prism Version
5.0a software (GraphPad Software) for Macintosh Pro personal computer.
Results
Induction of NHL cross-reacting Ab after DC-based vaccination
We set out to determine whether vaccine-induced antitumor Ab
response is directed against shared lymphoma-restricted antigens.
Total Igs isolated from patients’ serum samples, collected before
and after vaccination, were biotinylated and then tested by IHC on
allogeneic tumor specimens. IHC revealed tumor-restricted cross-
reactivity only when postvaccination Igs from responders were
used (Figure 1Ai; supplemental Figure 1, available on the Blood
Web site; see the Supplemental Materials link at the top of the
online article). There were no differences in the immunostaining of
pre- and postvaccination Igs from nonresponders (Figure 1Aii for a
representative example). To determine whether the Ab-recognized
tumor-specific antigens were expressed on the cell surface, biotin-
conjugated patients’ Igs were tested by flow cytometry on live
NHL, either cell lines or primary tumors, and normal B and T cells
(Figure 1B). Vaccine-induced Ab responses to cell-surface tumor-
specific antigens, evaluated as the ratio between post- and prevacci-
nation Ig reactivity, were significantly higher in responders com-
pared with nonresponders (Figure 1B). As shown in Figure 1B, the
ability of postvaccination Igs from responders to recognize live
tumor cell lines and primary cells increased by an average of
18-fold and 8-fold, respectively, compared with normal B cells
(top). By contrast, post-vaccination Igs from nonresponders did not
react with significantly enhanced efficiency on live tumor versus
normal B cells (Figure 1B bottom). Western blot (WB) analyses of
DOHH-2 cell extract using Igs from responders and nonresponders
revealed a sharp band migrating at approximately 100-110 kDa
only when post-vaccination Igs from responders were used (Figure
1C). No reactivity was observed in the same molecular weight
interval when prevaccination samples from these responders (Fig-
ure 1C left lanes 1) or pre- and postvaccine Igs from nonre-
sponders (Figure 1C right) were used. Further proof of the
induction of an antitumor Ab response in these patients was
provided by the finding that postvaccination serum from respond-
ers mostly displayed a higher pattern of reactivity on the whole
DOHH-2 proteome than the matched prevaccine samples (Figure
1C left).
Serological identification of HSP105 in NHL
For the discovery of proteins contained in the band migrating at
approximately 110 kDa, which was differentially recognized by
post-vaccination Igs from responders (Figure 1C left lanes 2), we
applied an appropriately modified SERPA. DOHH-2 protein ex-
tract was separated by isoelectrofocusing into 24 fractions (F1-24,
pH 3-9.57) to be individually loaded on 1-dimensional SDS-PAGE
and screened by WB analysis with responder’s pre- and post-
vaccination sera that showed the highest differential reactivity
against total DOHH-2 cell lysate (Figure 1C responder 14). An
increased ability of post- versus prevaccination Igs to immunostain
proteins migrating at approximately 100 to 110 kDa was found in
F6 (Figure 2Ai vs Figure 2Aii). MALDI-TOF-MS analysis,
performed in that molecular weight range of a silver-stained
preparative gel, identified in F6, and not in the nonreactive adjacent
HSP105 AS A NOVEL TARGET IN B-CELL LYMPHOMAS 4423BLOOD, 20 OCTOBER 2011  VOLUME 118, NUMBER 16
For personal use only.on November 10, 2016. by guest  www.bloodjournal.orgFrom 
F5 and F7, U5S1 (component of the U5 small nuclear ribonucleo-
protein particle), puromycin-sensitive aminopeptidase, mini-
chromosome maintenance proteins-4 (a DNA helicase activity
factor), all constitutively expressed in the nucleus or cytoplasm,
and HSP105, as the potential proteins differentially recognized by
post-vaccination Igs (Figure 2Bi). In light of the possibility that
HSP105 could be expressed on cell surface21 and the widely
described roles of HSP family members in a broad range of
neoplastic processes,10,13,22 we focused our study on understanding
HSP105’s involvement in B-NHL. The MS results were first
validated by WB analysis of F6 with anti-HSP105 Ab (Figure
2Bii). In addition, immunoprecipitation of HSP105 from DOHH-2
Figure 1. Antitumor cross-reactivity of vaccine-induced Igs in re-
sponders. (A) Representative IHC evaluations of biotin-conjugated pre-
(left) and postvaccination (right) Igs from responder 14 (i) and nonre-
sponder 2 (ii) tested on allogeneic human FL specimens. Digital images
were acquired with Nikon DN100 digital net camera and the Nikon Eclipse
E400 microscope, and processed using Photoshop CS4 software version
for Macintosh Pro personal computer. Original magnifications: pan-
els, 10; insets, 40. (B) Flow cytometry of normal B (CD19) and T (CD3)
cells, NHL cell lines (RL-19 and DOHH-2), and 4 different primary FLs (TM
1-4) using biotin-conjugated Igs from responders (top) and nonresponders
(bottom) and FITC-labeled streptavidin as revealing system. Results are
represented as the ratio between MFI of post- and prevaccination
samples. Data are mean  SE of 4 independent experiments. (C) WB
analyses of DOHH-2 whole lysate probed with biotin-conjugated Igs
purified from pre- (lanes 1) and post- (lanes 2) vaccination serum from
responders 13, 14, 1, and 5 (left) and nonresponders 2, 8, and 17 (right).
Arrow indicates the differentially revealed proteins. CR indicates complete
responder; and PR, partial responder.
Figure 2. Serological identification of HSP105 in B-NHL. (A) WB
analysis of OFFGEL fractions from DOHH-2 proteins (F5, F6, and F7)
probed with prevaccination (i) and postvaccination (ii) Igs from responder
14. (B) Silver staining of F5, F6, and F7 preparative SDS-PAGE for MS of
the numbered protein bands (i) and WB analysis of F6 probed with
polyclonal anti-HSP105 Ab (ii). (C) Immunoprecipitation (IP) of HSP105
from DOHH-2 whole cell lysate with polyclonal anti-HSP105 Ab, followed
by WB analysis using pre- and postvaccination (Vax) Igs from responder
14, or mouse anti-HSP105 mAb as control. pI indicates isoelectric point.
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cell extract using a specific Ab, followed by WB analysis with pre-
and post-vaccination Igs from responder 14, confirmed that vacci-
nation induced Abs directed against HSP105 (Figure 2C). The
other differentially recognized proteins were not considered be-
cause of their intracellular expression and their already known
structural functions.23-25
Expression of HSP105 in human NHL cell lines and primary
tumors
To investigate the involvement of HSP105 in B-NHL, we studied
its expression in a panel of human B-cell lymphoma cell lines
(Figure 3 columns 2-13), including low- (Figure 3 columns 2-5)
and high-grade NHLs (Figure 3, columns 6-10) and T-cell malignan-
cies (Figure 3 columns 15 and 16) and their normal cell counter-
parts (Figure 3 columns 1 and 14) by flow cytometry. Interestingly,
in B-NHL cell lines, the surface expression of HSP105, measured
both as median fluorescence intensity (MFI; Figure 3A left) and
positive cell percentage (Figure 3A right), tended to increase in
function of the degree of lymphoma aggressiveness. HSP105 was
expressed on the surface of 	 50% of normal circulating B cells
(Figure 3A right column 1). Donor PB T lymphocytes and cell lines
derived from T-cell leukemia and lymphoma did not express
HSP105 on their surface (Figure 3A columns 14-16). As expected,
HSP105 was expressed within the cytoplasm of all the cell lines
tested (Figure 3B). However, intracellular staining was heteroge-
neous in B-cell malignancies (Figure 3B columns 2-13), whereas it
was comparably high in normal and neoplastic T cells (Figure 3B
columns 14-16). WB analysis of these cell lines disclosed variable
expression levels of both the - and the 
-isoforms of HSP105
(supplemental Figure 2 lanes 2-13, 15, and 16), whereas normal B
and T cells preferentially expressed the constitutive cytoplasmic
HSP105- variant, represented by the one migrating at the highest
molecular weight26,27 (supplemental Figure 2 lanes 1 and 14).
IHC was then used to compare the expression of HSP105 in
97 human primary B-NHL specimens (54 indolent and 43 aggres-
sive lymphomas) and 26 nonmalignant lymph nodes. To quantify
HSP105 reactivity in tissue sections, we defined a CS, ranging from
0 to 7, that took into account both HSP105-positive cell percentage
and staining intensity. A CS  4 was arbitrarily considered as a
threshold value that mainly discriminated between the low- and the
high-grade B-NHLs (Figure 4A). IHC analysis of the tumor
biopsies from vaccinated patients (10 of 18) revealed no significant
differences in HSP105 expression level in function of their clinical
outcome (P  .625), indicating that the lack of response was not
the result of a reduced lymphoma expression of HSP105 (Figure
4Ai, white represents responders; and gray, nonresponders). HSP105
expression was significantly higher in the aggressive compared
with the indolent B-NHLs or normal lymph nodes (Figure 4Ai,
P  .001, and supplemental Figure 3 for representative examples)
and was directly correlated with the lymphoma histologic grade
(Figure 4Ai, P  .0001, Spearman r  0.6951). In addition, high-
proliferating tumors, characterized by an intense and widespread
Ki-67 staining ( 50% Ki-67 nuclei), expressed HSP105 at
significantly higher levels compared with the low-proliferating
forms ( 50% Ki-67 nuclei; Figure 4Aii, P  .001). The lym-
phoma proliferation rate thus correlated with HSP105 expression
levels (Figure 4Aii, P  .0001, Spearman r  0.7473).
Even in indolent B-NHLs, where the structure of the follicles
was preserved, HSP105 was preferentially expressed in the germi-
nal center (GC) lymphocyte-enriched areas (Figure 4Bi right),
which also stained strongly for Ki-67 (Figure 4Bi middle).
Neoplastic follicles of low-grade FLs highlighted an intense
expression of HSP105 in large cells corresponding to centroblasts,
whereas small neoplastic centrocytes displayed a milder immunore-
activity (supplemental Figure 3A). Consistent with HSP105 expres-
sion paralleling the degree of B-cell clone aggressiveness, immuno-
staining revealed diffuse and intense HSP105 expression in the
neoplastic infiltrates of DLBCL (supplemental Figure 3B) and BL
(supplemental Figure 3C).
To corroborate the significant direct correlation between tumor
aggressiveness and HSP105 expression levels, we used the histo-
logic samples from a patient who progressed from a low-grade
lymphoplasmacytic to a high-grade DLBCL after vaccination
(patient 15).9 Interestingly, a substantial increase of expression and
cell-surface localization of HSP105 was observed in the advanced
(Figure 4Bii bottom right) compared with the diagnostic lymphoma
Figure 3. Flow cytometry of HSP105 in malignant lymphoid cell lines
and normal cells. Surface (A) and intracellular (B) flow cytometric
analyses of normal B cells, (1) low-grade B-cell NHL cell lines DOHH-2,
(2) SC-1, (3) SU-DHL-6, and (4) KARPAS-422, (5) high-grade B-cell
NHL cell lines RL-19, (6) SU-DHL-4, (7) RAJI, (8) NAMALWA, and
(9) GRANTA-519, (10) Hodgkin lymphoma cell lines L-540 (11) and
HDMYZ, (12) multiple myeloma cell line KMS-11, (13) normal T cells,
(14) malignant T cell lines MOLT-4 (15), and SU-DHL-1 (16) stained with
rabbit polyclonal antihuman HSP105 Ab and FITC-labeled antirabbit
IgG. HSP105 relative MFI, calculated as the ratio between stained
samples and negative control MFI values (left panels), and percentage
of HSP105 cells (right panels). Data are mean  SE of 6 independent
experiments.
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(Figure 4Bii top right). The IHC results as a whole were in
complete agreement with the quantitative flow cytometry analyses
of cell-surface HSP105 levels on B-NHL cell lines (Figure 3A).
Antitumor activity of HSP105 targeting
The antitumor effects exerted by anti-HSP105 Ab were first
investigated in vitro on DOHH-2, SU-DHL-4, and NAMALWA
cell lines. Unexpectedly, the treatment did not provide any direct
cytotoxic or cytostatic antitumor activity (Figure 5A-C). As shown
in Figure 5A, no decrease in tumor cell proliferation rate was
observed in both indolent and aggressive NHL cell lines treated
with different concentrations of anti-HSP105 Ab. In keeping with
this finding, neither tumor cell death nor cell cycle arrest was
enhanced by the direct engagement of lymphoma cell-surface
HSP105 (Figure 5B-C).
Furthermore, WB analyses of molecules mediating DNA-
damage-repair functions and/or apoptosis (ie, RAD51, PARP, p53)
did not reveal any significant modulation when SU-DHL-4 or
NAMALWA cells were incubated in vitro with anti-HSP105 Ab at
different time points (supplemental Figure 4).
However, because of the high surface expression of HSP105 in
aggressive B-NHLs, we evaluated the immune-mediated antitumor
effects of its targeting through a specific Ab in SCID mice subcutane-
ously implanted with SU-DHL-4 (Figure 5Di) or NAMALWA
(Figure 5Dii) cells. Administration of anti-HSP105 Ab when
xenografts became palpable significantly reduced the tumor burden
in both xenografted models with respect to the control groups
injected with the matched isotype Igs or saline (Figures 5D). After
only 2 treatments with anti-HSP105 Ab, SU-DHL-4 and NA-
MALWA tumors displayed an average tumor shrinkage of 60% and
70%, respectively, compared with the rabbit IgG-injected controls
(Figure 5D; P  .001). These findings were also confirmed by
NMR in both xenograft models (supplemental Figure 5). The
greater NAMALWA tumor shrinkage compared with that of
SU-DHL-4 (Figure 5D) was probably the result of the higher
cell-surface expression level of HSP105 in NAMALWA cells
(Figure 3A).
NAMALWA xenografts (supplemental Figure 6A), as defined
by CD45 staining (supplemental Figure 6B), expressed Ki-67
(supplemental Figure 6C) and HSP105 (supplemental Figure 6D)
at levels superimposable on those observed in human high-grade
primary B-NHL specimens (Figure 4Bii bottom; supplemental
Figure 3C). A marked increase of necrotic areas was detected in
anti-HSP105 Ab-treated xenografts with respect to the controls, as
revealed by hematoxylin and eosin stainings (Figure 6Ai bottom vs
top, for representative examples). Under low power, untreated
tumors displayed the typical “starry-sky” pattern of BL, indicating
the presence of apoptotic tumor cells (Figure 6Ai top). On HSP105
targeting, the tumor xenografts showed signs of single-cell necrosis
and extended necrotic foci, which involved both lymphoid neoplas-
tic cells and the branching fibrovascular stromal network (Figure
6Ai bottom). Necrotic changes characterizing anti-HSP105 Ab-
treated lymphomas were associated with a significant infiltration of
NK cells, highlighted by Granzyme B (Figure 6Aii bottom vs top)
and CD56 immunostaining (Figure 6Aiii bottom vs top), suggest-
ing the contribution of Ab-dependent cell-mediated cytotoxicity
(ADCC) to the antitumor activity of this Ab-based immunotherapy,
as already described for other Abs in different tumor models.28
Quantitative evaluation of tumor-infiltrating Granzyme B (Figure
6Bi) and CD56 cells (Figure 6Bii), which were counted in 5
high-power microscopic fields in sections from anti-HSP105 Ab-
and isotype Ig-treated xenografts, reproducibly confirmed this
finding.
Discussion
In the present study, we identify HSP105 as a novel potential
therapeutic biotarget in B-NHLs. Specifically, starting from the
observation that DC-based vaccination in NHL patients enhanced
the frequency of circulating Abs directed against shared lymphoma
antigens only in responders, an appropriately modified SERPA
applied to a NHL cell line proteome revealed HSP105 as one of the
possible responders’Ab-targeted proteins. The cell-surface expres-
sion of HSP105 correlated with B-NHL proliferation rate and
aggressiveness in both cell lines and primary tumors. Despite the
lack of direct proapoptotic and cytostatic in vitro activity of an
Figure 4. Immunohistochemistry of HSP105 expression in normal and neoplas-
tic lymph nodes. (A) HSP105 expression levels measured by IHC using the defined
CS in B-NHLs (97 cases) and nonmalignant lymph nodes (26 cases) plotted against
tumor aggressiveness based on lymphoma histologic grade (i) or Ki-67 expression
levels (ii). HSP105 CS in tumor biopsies from vaccinated patients is highlighted
(white represents responders; and gray, nonresponders). The lines indicate the
median values. Significant differences of HSP105 expression between groups were
calculated with the unpaired 2-tailed Student t test: **P  .01; ***P  .001. Correla-
tion between HSP105 expression and lymphoma aggressiveness was determined
with the Spearman rank correlation test. LN indicates lymph nodes; HG, high grade;
and LG, low grade. (B) Representative IHC analyses of low- and high-grade B-NHLs,
using streptavidin-biotin-HRP complex method with 3-3 diaminobenzidine as a
chromogen (brown signal). Hematoxylin and eosin (left), Ki-67 (middle), and HSP105
(right) staining in one case of FL (i) and lymphoplasmocytic lymphoma (ii) before (top)
and after progression (bottom) toward a DLBCL. Arrows indicate HSP105 expression
on lymphoma cell surface. Digital images were acquired with Nikon DN100 digital net
camera and the Nikon Eclipse E400 microscope, and processed using Photoshop
CS4 software version for Macintosh Pro personal computer. Original magnifications:
Bi, 10; and Bii, 20.
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HSP105-specific Ab, its administration in SCID mice significantly
delayed and impaired the growth of aggressive human B-NHL
xenografts. Because HSP105 engagement by this Ab favored the
recruitment of CD56, Granzyme B-releasing killer cells at the
tumor site, we speculate that ADCC may have exerted a major role
in promoting the extended necrosis observed in anti-HSP105
Ab-treated tumor tissue compared with the control tumor biopsies.
The management of NHL patients has been considerably
improved by the introduction of mAb therapy. Addition of the
anti-CD20 mAb rituximab to conventional and high-dose chemo-
therapy protocols has significantly ameliorated the prognosis of
B-NHLs.5 Despite this clinical success, resistance occurs in
approximately half of the treated patients, resulting in nonresponse
to treatment or early relapse.6,7 Hence, different NHL biotargets
and more potent mAbs are continuously being sought.
The finding that DC vaccination induced the development of
lymphoma-specific Abs only in responders led to the serological
discovery of novel potential NHL therapeutic targets through
exploitation of the Ab repertoires from vaccinated patients. For this
purpose, we applied a high-resolution 2-step SERPA to circumvent
the limitations of the classic 2-dimensional SDS-PAGE approach to
barely detect low-molecular-weight proteins and those with ex-
treme pH, as well as low-abundance and poorly soluble hydropho-
bic proteins, such as cell-surface proteins.29,30 This strategy success-
fully revealed a pattern of increased reactivity for post- compared
with pre-vaccination Abs from responders on a B-NHL-proteome,
and MS identified HSP105 as one of the cell-surface antigens
differentially recognized. There is little information on how HSP
regulation is subverted in cancer and how it affects the molecular
events involved in tumor growth, invasiveness, and metastasis.11
Figure 5. In vitro and in vivo antilymphoma activity of
anti-HSP105 Ab. (A) DOHH-2 (i), SU-DHL-4 (ii), and
NAMALWA (iii) cells were treated with the indicated
concentrations of the anti-HSP105 Ab formulation for in
vivo use; and after being stained with PI, viable cells in
culture (PI) were counted by flow cytometry using a
calibrated suspension of fluorescent microspheres at the
indicated time points (h indicates hours). The plots show
the means of 3 independent experiments. (B) Flow
cytometric determinations of apoptosis of the cell cul-
tures described in panel A costained with FITC-labeled
annexin V (ANN) and PI. Average percentages of
ANNPI (white), ANNPI (light gray), ANNPI (dark
gray), and ANNPI (black) cells in cultures, calculated
from the results of 3 independent experiments, are
shown. (C) Flow cytometry-based cell-cycle analyses of
DOHH-2 (i), SU-DHL-4 (ii), and NAMALWA (iii) cells after
72-hour incubation with anti-HSP105 Ab at the indicated
concentrations.Average frequencies of cells in G1 (black),
S (white), and G2 (gray) cell-cycle phases and SD of
3 independent experiments are shown. (D) SU-DHL-4 (i)
and NAMALWA (ii) growth in SCID mice treated with
3 intraperitoneal injections of NaCl solution (ctrl), 250 g
anti-HSP105 Ab, or matched isotype Igs (rabbit IgG)
every 4 days (black arrows). Average tumor volumes
(measured with calipers) and SE of 2 (SU-DHL-4 model)
and 3 (NAMALWA model) independent experiments, in
which 6 mice per group were analyzed. Statistically
significant differences were calculated by using the 2-way
ANOVA: **P  .01; ***P  .001. Black stars represent
anti-HSP105 Ab versus rabbit IgG; and gray stars,
anti-HSP105 Ab versus ctrl.
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However, it seems that HSP can modulate both proapoptotic and
antiapoptotic pathways.16,13 In addition, extracellular or membrane-
bound HSPs, mainly HSP90 and HSP72, can induce T-cell
activation because of their carrier function for antigenic peptides
and their ability to deliver direct immune-activating signals.18,31,32
It is therefore possible that DC vaccination provided HSP105-
peptide complex to the host immune system and/or activated it
toward multiple tumor-associated antigens, including HSP105, and
favored the onset of a clinical response.
Human HSP105 is a high-molecular-weight chaperone protein
expressed at constitutively low levels as a cytoplasmic -isoform
and as an inducible nuclear 
-isoform on exposure to various forms
of stress.27 However, in several solid tumors, including melanoma,
breast, thyroid, and gastroenteric cancers, HSP105 is constitutively
overexpressed33-35 and exerts antiapoptotic functions.36-38 HSP105
had also been previously defined by serological-recombinant
expression cloning technique, using serum samples from pancre-
atic and colorectal carcinoma patients.33 This provides a further
illustration of its immunogenic properties in cancer patients.
Importantly, several preclinical studies have demonstrated that
preventive immunization against HSP105 provides a significant
antitumor activity.39,40 A very recent report has demonstrated the
expression of HSP105 in the cytoplasm and within the nucleus of
Hodgkin/Reed-Sternberg cells of classic Hodgkin lymphoma15;
however, no previous studies have already shown the cell surface
expression of HSP105 in B-NHLs.
Here, we demonstrated a significant direct correlation between
HSP105 expression levels and B-NHL aggressiveness and prolifera-
tion. Its up-regulation during disease progression from indolent to
aggressive NHL further corroborated these findings, which, collec-
tively, point to HSP105 as a novel candidate biomarker of
lymphoma aggressiveness. Our results in lymphoma are in line
with previous demonstrations in solid tumors of the association
between HSP105 up-regulation in tumor tissue and disease progres-
sion.35,41 The finding of an HSP105 intermediate cell-surface
expression on donor circulating B cells, which are professional
antigen-presenting cells, could be explained by the already reported
function of HSPs in antigen cross-presentation.32,42
In agreement with a recent report demonstrating the ability of
HSP90 to stabilize BCL-6 in normal centroblasts during the affinity
maturation process,43 the preferential localization of HSP105
within the GCs of low-grade lymphomas and normal lymph nodes
(data not shown) indicates that GC reaction may be governed by a
stress response that may itself be involved in the physiopathology
of GC-derived B-cell lymphomas. In keeping with this hypothesis,
overexpression of the alternative splicing variant HSP105
 has
been found to stimulate the phosphorylation of STAT3,26,27,44,45
which constitutes a crucial signaling node of B-NHLs.46-48 Increas-
ing evidence is pointing to the stress response pathway as an
additional hallmark of cancer and a promising new target for
anticancer therapy.13 Tumor cells, indeed, require HSPs to maintain
normal homeostasis of their altered proteome and cope with the
potentially lethal conditions in which they are forced to grow, and
for the correct maturation and function of several oncoproteins.13,49
Remarkably, direct targeting of HSP105 with a specific Ab
demonstrated a significant antitumor activity against highly aggres-
sive human lymphoma cell lines in vivo. No significant off-target
toxicity was documented after targeting HSP105 in xenografted
lymphoma mouse models. However, the mechanisms accounting
for the in vivo antitumor effects of the anti-HSP105 Ab used in our
study seem to essentially rely on its ability to activate ADCC at the
tumor site. The engagement of surface-HSP105 with this Ab,
Figure 6. Antitumor effects of HSP105 targeting in the NAMALWA
model. (A) IHC of NAMALWA xenografts from control rabbit IgG- (top) and
anti-HSP105 Ab-treated (bottom) animals. Representative hematoxylin
and eosin (i), Granzyme B (ii), and CD56 (iii) stainings. Digital images were
acquired with Leica DFC320 digital camera and Leica DM2000 micro-
scope, and processed using Photoshop CS4 software version for Macin-
tosh Pro personal computer. Original magnifications: i, 200; ii,iii, 400;
and insets, 400. (B) Absolute number of Granzyme B (i) and CD56 (ii)
cells in sections from control rabbit IgG- and anti-HSP105 Ab-treated
xenografts. Immunoreactive cells (ie, yellow/brown-stained cells) were
counted in 5 high-power microscopic fields (original magnification, 400)
for each condition, and the result was expressed as an average. The
boxes extend from the 25th to the 75th percentiles, the lines indicate the
median values, and the whiskers indicate the range of values. Results
from 2 independent experiments are shown. Statistically significant differ-
ences between groups were assessed with the unpaired 2-tailed Student
t test: ***P  .001.
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indeed, did not alter any of the crucial signaling pathways
associated with tumor-cell proliferation and survival as well as
DNA-damage response, including those mediated by p53, PARP,
RAD51, and MAPK and AKT (data not shown).
The development of novel functional anti-HSP105 mAbs as
well as the use of specific blocking peptides will clarify the
functional role of HSP105 in B-NHLs and also show whether it can
be added to the growing list of not merely oncogenic molecules13,49
that may represent equally valid targets for anticancer therapy.
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